Skip to main content
. 2021 Feb 14;7(1):e12106. doi: 10.1002/trc2.12106

FIGURE 2.

FIGURE 2

a, Twenty‐four‐week change in FDG SUVR in placebo‐ versus rasagiline‐treated patients. b, Longitudinal voxel‐based classifier results showing regions where rasagiline‐treated participants declined less in glucose metabolism than placebo‐treated participants